Headlines about LivaNova (NASDAQ:LIVN) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LivaNova earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.0227248783493 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Several equities analysts recently commented on the stock. Zacks Investment Research cut shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine cut shares of LivaNova from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 12th. Canaccord Genuity reiterated a “hold” rating and set a $76.00 target price on shares of LivaNova in a research note on Tuesday, December 5th. Finally, Needham & Company LLC upped their target price on shares of LivaNova from $93.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $79.71.
LivaNova (LIVN) traded up $0.61 during trading hours on Tuesday, reaching $82.08. 373,488 shares of the company traded hands, compared to its average volume of 355,133. LivaNova has a 1 year low of $45.67 and a 1 year high of $88.56. The firm has a market cap of $3,930.00 and a PE ratio of 21.89. The company has a current ratio of 2.03, a quick ratio of 1.42 and a debt-to-equity ratio of 0.04.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.17. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The company had revenue of $309.70 million during the quarter, compared to analysts’ expectations of $301.22 million. During the same quarter in the prior year, the company posted $0.78 EPS. The business’s revenue was up 4.9% on a year-over-year basis. research analysts forecast that LivaNova will post 3.24 EPS for the current fiscal year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $81.39, for a total value of $81,390.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hugh M. Morrison sold 1,830 shares of the stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $88.00, for a total transaction of $161,040.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,830 shares of company stock valued at $569,350. Corporate insiders own 0.28% of the company’s stock.
WARNING: This piece was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international trademark and copyright law. The legal version of this piece can be read at https://transcriptdaily.com/2018/01/10/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-livanova-livn-stock-price.html.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.